Navigation Links
EpiDerm's Skin Irritation Test Fully Validated in European Union
Date:12/17/2008

Significant milestone met in development and validation of non-animal alternative test methods

ASHLAND, Mass., Dec. 17 /PRNewswire/ -- MatTek Corporation today announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the scientific validity of the Modified EpiDerm Skin Irritation Test (SIT) at its November meeting. ESAC concluded that the Modified EpiDerm SIT has sufficient accuracy and reliability for the prediction of skin irritating and non-irritating test substances.

The Updated EpiDerm SIT is a modification of the previously validated EpiDerm skin irritation method (ESAC Statement, April 2007). The major modification is an extended chemical exposure time from 15 to 60 minutes that reflects the robust barrier function of the EpiDerm model. The new exposure time provides an improved sensitivity of the in vitro EpiDerm SIT and better correlation with in vivo Draize rabbit skin irritation results.

The Modified EpiDerm SIT eliminates the need for animal testing when used to determine skin irritation potential of chemicals, including raw cosmetic materials. This development allows companies world-wide to comply with new European Union (EU) REACH legislation as well as the EU directive on the protection and welfare of animals used for experimental and other scientific purposes. This directive (EU 86/609) prohibits the use of animals in experiments if a validated alternative is available.

The Modified EpiDerm SIT will also be of great benefit to the Cosmetic Industry because testing of cosmetic raw materials in animals will be prohibited in the EU beginning March 2009 (7th Amendment of EU Cosmetic Directive).

John Sheasgreen, MatTek's President, added, "The validation of the Modified EpiDerm SIT involved multiple successful transatlantic tissue shipments from MatTek's US production facility to EU testing laboratories. The ability to ship EpiDerm tissues in this manner is yet another reason why MatTek has become the supplier of choice for both European and US organizations testing safety and efficacy of finished products and ingredients."

The Modified EpiDerm SIT validation study on which ECVAM based its new statement was performed under the auspices of ZEBET (BfR) in 4 independent EU and US laboratories during 2007. The testing fully complied with all validation rules outlined by OECD and ICCVAM (e.g. independent study management, coded reference chemicals, inclusion of naive laboratory, etc.).

About MatTek - MatTek Corp., founded in 1985, is the world's largest independent producer of in vitro human epithelial tissue equivalents. MatTek maintains a database that currently contains over 400 technical references and over 10 years of publicly available QC data supporting its claim of "Unsurpassed Tissue Reproducibility." MatTek human tissue equivalents are used in product development, claims substantiation (over 100 company patents cite the use of MatTek tissues), safety assessment, and drug discovery/development in many industries including Cosmetics, Personal Care, Household Products, Chemicals, Pharmaceuticals and Biotech.


'/>"/>
SOURCE MatTek Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
5. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
6. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
7. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):